Latest news

• Merck and Ridgeback fulfil US deal for molnupiravir

  Over three million courses of the investigational oral antiviral COVID-19 treatment have been supplied. ... Merck &Co – known as MSD outside the US and Canada – and Ridgeback Biotherapeutics have announced that approximately 3.1 million courses of

• Pfizer's oral antiviral Paxlovid significantly cuts risk of severe COVID-19

  Only a few days after the UK approved the use of the first oral antiviral to treat COVID-19, Merck’s Lagevrio, Pfizer has ceased enrolment in its phase 2/3 ... In its announcement, Pfizer highlighted that, if approved, Paxlovid would be the first oral

• Merck’s COVID-19 antiviral under review in Europe by EMA

  Molnupiravir could be the first oral antiviral treatment for COVID-19 in Europe for patients at risk of severe disease. ... If approved, molnupiravir would be the first oral antiviral for use against COVID-19 in Europe.

• Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir

  If authorised, molnupiravir could be the first oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in at risk adults. ... Molnupiravir is an investigational oral antiviral medicine for the treatment of mild-to-moderate COVID-19 in

• Merck and Ridgeback’s oral antiviral halves COVID-19 risk of hospitalisation or death

  Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at ... If authorised,